These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17224890)

  • 41. A decade of improvement in the clinical outcomes of percutaneous coronary intervention for multivessel coronary artery disease.
    Popma JJ; Kuntz RE; Baim DS
    Circulation; 2002 Sep; 106(13):1592-4. PubMed ID: 12270845
    [No Abstract]   [Full Text] [Related]  

  • 42. Optimal treatment of the diabetic patient with multivessel disease.
    Bansilal S; Farkouh ME; Fuster V
    Curr Cardiol Rep; 2008 Jul; 10(4):272-84. PubMed ID: 18611361
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of oxidative stress on chronic kidney disease progression.
    Putri AY; Thaha M
    Acta Med Indones; 2014 Jul; 46(3):244-52. PubMed ID: 25348188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).
    Herzog CA; Asinger RW; Berger AK; Charytan DM; Díez J; Hart RG; Eckardt KU; Kasiske BL; McCullough PA; Passman RS; DeLoach SS; Pun PH; Ritz E
    Kidney Int; 2011 Sep; 80(6):572-86. PubMed ID: 21750584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cross-talk between primary percutaneous coronary intervention, arterial inflammation, and light/dark patterns.
    Dominguez-Rodriguez A; Bosa-Ojeda F; Abreu-Gonzalez P
    JACC Cardiovasc Interv; 2009 Apr; 2(4):368; author reply 368-9. PubMed ID: 19463454
    [No Abstract]   [Full Text] [Related]  

  • 46. Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients.
    Lovre D; Shah S; Sihota A; Fonseca VA
    Endocrinol Metab Clin North Am; 2018 Mar; 47(1):237-257. PubMed ID: 29407054
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Introducing the 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and CVD.
    Aboyans V
    Eur Heart J; 2019 Oct; 40(39):3217-3219. PubMed ID: 31608953
    [No Abstract]   [Full Text] [Related]  

  • 48. Beyond a Measure of Liver Function-Bilirubin Acts as a Potential Cardiovascular Protector in Chronic Kidney Disease Patients.
    Tsai MT; Tarng DC
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597982
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The old is new: Lipid therapy and CKD.
    Dobkowski D; Thompson ME
    JAAPA; 2015 May; 28(5):18-22. PubMed ID: 25909538
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Nutritional approach of the patient with diabetes mellitus and chronic kidney disease. A case report].
    Torres Torres B; Izaola Jáuregu O; De Luis Román DA
    Nutr Hosp; 2017 May; 34(Suppl 1):18-37. PubMed ID: 28585854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease.
    Robey RB; O'Rourke DJ
    Ann Intern Med; 2012 Aug; 157(4):302-3; author reply 303-4. PubMed ID: 22910952
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease.
    Kussmaul W
    Ann Intern Med; 2012 Aug; 157(4):302; author reply 303-4. PubMed ID: 22910951
    [No Abstract]   [Full Text] [Related]  

  • 53. Cardiovascular complications of chronic kidney disease.
    Ross L; Banerjee D
    Int J Clin Pract; 2013 Jan; 67(1):4-5. PubMed ID: 23241045
    [No Abstract]   [Full Text] [Related]  

  • 54. Blood pressure guidelines as starting point in clinical decisions.
    Krumholz HM
    BMJ; 2018 Jan; 360():j5862. PubMed ID: 29295826
    [No Abstract]   [Full Text] [Related]  

  • 55. Risk stratification in diabetic patients: a continuing challenge.
    Miller TD; Shaw LJ
    J Nucl Cardiol; 2009; 16(4):486-9. PubMed ID: 19536606
    [No Abstract]   [Full Text] [Related]  

  • 56. Novel combined management approaches to patients with diabetes, chronic kidney disease and cardiovascular disease.
    Spaak J
    J R Coll Physicians Edinb; 2017 Mar; 47(1):83-87. PubMed ID: 28569290
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cochrane Corner: evaluation of the Cochrane systematic review "antiplatelet agents for chronic kidney disease".
    Caldeira D; Vaz-Carneiro A; Costa J
    Rev Port Cardiol; 2013 Nov; 32(11):917-8. PubMed ID: 24268867
    [No Abstract]   [Full Text] [Related]  

  • 58. [Diabetes mellitus related common medical disorders recent progress in diagnosis and treatment. Topics: I. Pathophysiology, diagnosis and treatment; 7. Chronic kidney disease. ].
    Haneda M
    Nihon Naika Gakkai Zasshi; 2013 Apr; 102(4):875-81. PubMed ID: 23772501
    [No Abstract]   [Full Text] [Related]  

  • 59. [Chronic Kidney Disease].
    Wanner C; Ketteler M
    Dtsch Med Wochenschr; 2017 Feb; 142(3):193-196. PubMed ID: 28187484
    [No Abstract]   [Full Text] [Related]  

  • 60. The role of antiplatelets in hypertension and diabetes mellitus.
    Ajjan RA; Grant PJ
    J Clin Hypertens (Greenwich); 2011 Apr; 13(4):305-13. PubMed ID: 21466631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.